Evidence-based medicine or ORIGIN study lessons (Outcome Reduction with Initial Glargine INtervention)

• Alexander S. Ametov
• Elena V. Doskina

Abstract

One of the most significant and global studies of the last decade is ORIGIN (Outcome Reduction with Initial Glargine INtervention-reducing the effects of diabetes mellitus by early administration of insulin glargine) -a comparison of the treatment with Lantus (insulin glargine 100 U/ml) with standard hypoglycemic therapy in terms of time the development of the first major cardiovascular complication. The results obtained in a long-term study proved the effectiveness of insulin therapy (glargine 100 U/ml), cardio and cancer safety.

Keywords:diabetes mellitus, insulin therapy, insulin Glargine, evidence-based medicine, ORIGIN

Литература/References

1. Sackett D. L., Rosenberg W. M., Gray J., et al Evidence based medicine: what it is and what it isn’t. BMJ. 1996; 312 (7023): 71.

URL: https://www.bmj.com/content/312/7023/71

DOI: 10.1136/bmj.312.7023.71

2. ORIGIN Trial Investigators. Diabetes Care. 2016; 39: 709-16.

URL: https://www.ncbi.nlm.nih.gov/pubmed/26681720

DOI: 10.2337/dc15-1676

3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-53.

URL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)07019-6/fulltext

DOI: https://doi.org/10.1016/S0140-6736(98)07019-6

4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854-65.

URL: https://www.ncbi.nlm.nih.gov/pubmed/9742977

DOI: https://doi.org/10.1016/S0140-6736(98)07037-8

5. The ADVANCE Collaborative Group. N Engl J Med. 2008; 358: 2560-72.

URL: https://www.ncbi.nlm.nih.gov/pubmed/18539916

DOI: 10.1056/NEJMoa0802987

6. ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease - preterax and diamicron MR controlled evaluation. Diabetologia. 2001; 44: 1118-20.

URL: https://www.ncbi.nlm.nih.gov/pubmed/11596665

DOI: 10.1007/s001250100612

7. Miriam E Tucker. New VADT Data: Hypoglycemia Is a Risk Factor for CVD in Some//2016,

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)